Alarcon 1989.

Methods	Randomized controlled trial Duration: dates not supplied. Participants followed up for 4 months
Participants	Number: 23 enrolled; numbers of males and females not presented Inclusion criteria: adults and children aged > 13 years, with 1 to 3 parenchymal cysts > 10 mm without perilesional oedema, good general health and stable neurological disease Exclusion criteria: parenchymal cysts with ring enhancement and oedema surrounding the lesions, pregnant women Type of lesion: viable
Interventions	Group 1. Albendazole: 15 mg/kg bodyweight for 3 days Group 2. Albendazole: 15 mg/kg bodyweight for 30 days Group 3. No albendazole
Outcomes	Included in the review: number of cysts and total diameter of cysts at baseline and 1 day, 30 days, and 3 months after treatment finishes. Adverse events
Notes	Location: Ecuador Source of funding: not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Quote: "randomly allocated" Decision: probably done, but unclear
Allocation concealment?	Unclear risk	Not described
Blinding? All outcomes	Unclear risk	Not described. Placebos were not used and different groups received follow‐up scans at different times Decision: unclear, probably not done
Incomplete outcome data addressed? All outcomes	Low risk	23 randomized and follow‐up data available for all (100%)
Free of selective reporting?	Low risk	No evidence of selective reporting; outcomes reported individually for all participants
Free of other bias?	Low risk	No evidence of other bias